Group items tagged

The global breast cancer drug market size is expected to reach USD 38.4 billion by 2025. It is projected to expand at a CAGR of 10.7% during the forecast period. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends stoking market growth. Global breast cancer drugs market is expected to grow lucratively as many players focus majorly on R&D of innovative treatments. They engage in extensive research to develop novel drugs for the treatment of the disease to gain a higher market share. There exists a growing pressure and need for novel therapies and treatment due to rapidly accelerating prevalence of diseases. The strong pipeline is expected to provide new and effective treatment options and improved outcomes than existing therapies. With advancements in drug delivery systems, various target specific therapies have been customized and designed as a carrier to infuse the therapeutic agent to the target site. Carriers for inducing target therapy include modified anticancer agent's specific to molecular-recognition-element, anticancer peptides, and nanoparticle-based anticancer drugs. For instance, HER2/neu protein is usually given in combination with other anti-cancer drugs in targeted therapy. Get Free Sample Copy of this Report at at: https://www.radiantinsights.com/research/breast-cancer-drugs-market/request-sample F. Hoffman-La Roche Ltd leads the breast cancer drugs market with Herceptin, Perjeta, and Kadcyla. However, rapid advancements in biosimilars with a goal to offer cost effective alternatives to patients is anticipated to put pressure on this space. For instance, in December 2017, the Food and Drug Administration (FDA) approved the first biosimilar of trastuzumab for HER2+ breast cancer. Further key findings from the report suggest: * HER2 inhibitors is expected to be the most preferred drug class segment over the forecast period, owing to their high specificity as they are subclass of target therapy *

"Breast Cancer Drugs Market Breast Cancer Drugs Industry Breast Cancer Drugs Cancer drugs"

"The global carbon black market size is projected to reach USD 25.95 billion by 2025 expanding at a CAGR of 6.0%. Increasing tire production on accounted of growing transportation industry is driving the product demand. Carbon black is a highly regulated industry as the manufacturing process is considered harmful owing to the toxic emissions, which have adverse effects on the environment and health. In February 2003, it was added to the California Office of Environmental Health Hazard Assessment (OEHHA) list of substances known to the State that cause cancer. Major companies in the market are focusing on R&D activities to develop new manufacturing techniques to reduce harmful emissions. Stringent regulations to curb emissions are expected to play a major role in driving the market growth. Emerging countries in Asia Pacific, such as China, Thailand, India, and Indonesia, are projected to generate the maximum product demand in the coming years. Manufacturers in North America and Europe regions are forced to shift their operations to Asian countries owing to low cost in emerging countries. However, recovery in the automotive industry in countries, such as Germany and France, is are anticipated to boost market growth in Europe over the forecast period."